TY - JOUR
T1 - Generic patient self-report and investigator report instruments of therapeutic safety and tolerability
AU - Lassere, Marissa N.D.
AU - Johnson, Kent R.
AU - Van Santen, Susanne
AU - Carlton, Kerri
AU - Rappo, Joy
AU - Michael, Rachel
AU - Kirwan, John R
AU - Edmonds, John P.
PY - 2005/10/1
Y1 - 2005/10/1
N2 - A patient self-report instrument was designed as a patient event index that maps to a parallel investigator instrument. Event importance (a composite of severity, frequency, and duration) was reported, but attribution was not required. The patient instrument used a checklist but also allowed for spontaneous reporting for new or unusual events. The investigator instrument (also a checklist) includes all events reported by the patient, as well as events such as signs, investigations, and diagnoses that would not generally be known to the patient. Presently, both patient and investigator instruments are to be used alongside current methods of adverse event reporting in clinical trials. The patient instrument would serve as a safety/tolerability index, whereas the investigator instrument would be a fully quantifiable (appropriately weighted), standardized adverse event index. As in many methodological projects in medicine, the overriding problem was the tradeoff between validity (comprehensiveness and accuracy) and feasibility (clarity and short administration time) in instrument development. A summary of pilot studies and results of instrument reliability and validity are presented.
AB - A patient self-report instrument was designed as a patient event index that maps to a parallel investigator instrument. Event importance (a composite of severity, frequency, and duration) was reported, but attribution was not required. The patient instrument used a checklist but also allowed for spontaneous reporting for new or unusual events. The investigator instrument (also a checklist) includes all events reported by the patient, as well as events such as signs, investigations, and diagnoses that would not generally be known to the patient. Presently, both patient and investigator instruments are to be used alongside current methods of adverse event reporting in clinical trials. The patient instrument would serve as a safety/tolerability index, whereas the investigator instrument would be a fully quantifiable (appropriately weighted), standardized adverse event index. As in many methodological projects in medicine, the overriding problem was the tradeoff between validity (comprehensiveness and accuracy) and feasibility (clarity and short administration time) in instrument development. A summary of pilot studies and results of instrument reliability and validity are presented.
KW - Adverse event
KW - Patient questionnaire
KW - Randomized controlled trials
UR - http://www.scopus.com/inward/record.url?scp=26444598470&partnerID=8YFLogxK
M3 - Article (Academic Journal)
C2 - 16206365
VL - 32
SP - 2033
EP - 2036
JO - Journal of Rheumatology
JF - Journal of Rheumatology
SN - 0315-162X
IS - 10
ER -